# Methylmalonic acidemia (MMA) (mRNA-3705)

*Last program update: May 6, 2021*

<table>
<thead>
<tr>
<th>Modality</th>
<th>ID #</th>
<th>Program Indication</th>
<th>Preclinical development</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3 and commercial</th>
<th>Moderna rights</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mRNA-3927</td>
<td>PCCA/PCCB Propionic acidemia, PA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Worldwide</td>
</tr>
<tr>
<td></td>
<td>mRNA-3705</td>
<td>MUT Methylmalonic acidemia, MMA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Worldwide</td>
</tr>
<tr>
<td></td>
<td>mRNA-3283</td>
<td>PAH Phenylketonuria, PKU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Worldwide</td>
</tr>
<tr>
<td></td>
<td>mRNA-3745</td>
<td>G6Pase Glycogen storage disease type 1a, GSD1a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Worldwide</td>
</tr>
</tbody>
</table>

**Systemic Intracellular therapeutics**
Organic acidemias

Multiple candidates targeting same metabolic pathway

MMA and PA

- Similar biology and disease pathology
- Shared treating clinicians and centers of excellence
- Relative prevalence in any given locale is a function of local founder effects/consanguinity
  - MMA: \(~500-2,000\) patients in the US*
  - PA: \(~325-2,000\) patients in the US*

*Based on estimated birth prevalence (MMA: 0.3-1.2:100,000 newborns; PA: 0.2-1.2:100,000 newborns) and mortality rates

mRNA advantages

- Ability to encode for intracellular proteins, localized to mitochondria
- Ability to titrate dose to response
- Potential to treat during acute metabolic decompensations
Methylmalonic acidemia (MMA) overview

- **Disease overview**: Rare, autosomal recessive organic acidemia/aciduria
  - Defective or deficient MUT enzyme (methylmalonic CoA mutase)

- Disease is progressive, involves multiple organ systems and is highly lethal; includes risk of life-threatening metabolic decompensation episodes

- Primarily a pediatric disease with onset in early infancy; significant mortality and morbidity

- **Prevalence**: ~1:100K (except in the Middle East where it is higher, 6:100K)

- **Treatment**: There is no approved therapy for MMA
  - Current interventions include: dietary restriction, cofactor therapy and carnitine
  - Liver and/or kidney transplant is the only effective treatment, even in infants (but transplant is not curative)

<table>
<thead>
<tr>
<th>Clinical manifestations</th>
<th>Neonatal period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Neurological complications</td>
</tr>
<tr>
<td></td>
<td>Growth retardation</td>
</tr>
<tr>
<td></td>
<td>High mortality</td>
</tr>
<tr>
<td></td>
<td>Life-threatening metabolic crises</td>
</tr>
<tr>
<td></td>
<td>Pancreatitis</td>
</tr>
<tr>
<td></td>
<td>Renal complications</td>
</tr>
</tbody>
</table>
Moving forward with next generation MMA candidate (mRNA-3705)

**MMA (mRNA-3705)**

- Introduction of a drug product with better pharmacology (new mRNA)
- Same LNP, also used in mRNA-1944
- Taken opportunity to revise clinical protocol to improve patient experience and operational feasibility
-Received rare pediatric disease designation for next generation MMA candidate (mRNA-3705)

**Next steps**

- File new IND and CTA applications for mRNA-3705

mRNA-3705 produces **higher levels of hMUT** enzyme in the liver of rats

mRNA-3705 showed **greater potency and prolonged lowering of MMA** in mut- mice

*P<0.05, ***P<0.001, ****P<0.0001 by one-way ANOVA followed by Tukey’s multiple comparisons test*
Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new potential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.